Abstract
Dopamine and glutamate have been shown to extensively interact in the striatum, nucleus accumbens, hippocampus and prefrontal cortex, to regulate different physiological functions, including locomotor activity, positive reinforcement, attention and working memory. Although dysfunctions of dopamine transmission have long been identified as critical determinants of neurological and neuropsychiatric disorders, such as Parkinsons disease and schizophrenia, there is now increasing evidence that concurrent alterations of dopamine and glutamate function may play a central role in the pathophysiology of these diseases. Thus, defining the characteristics of dopamine-glutamate interactions may be crucial to identify alternative molecular targets for the development of novel pharmacological tools. At the postsynaptic level, interactions between the dopamine D1 and the glutamate NMDA receptors appear to be particularly relevant. Different mechanisms are involved in this interactions: 1) D1R-dependent, second messenger-mediated phosphorylation of NMDAR subunits; 2) coordinated regulation of receptor trafficking at synaptic sites; 3) formation of an heteromeric D1/NMDA receptor complex. In this paper we review the molecular mechanisms, functional implications and pharmacological significance of D1R/NMDAR interaction via direct protein-protein oligomerization.
Keywords: glutamate transmission, cAMP-PKA pathway, bioluminescence resonance energy transfer (BRET), NMDA-mediated currents, Dopamine
Current Topics in Medicinal Chemistry
Title: The NMDA/D1 Receptor Complex as a New Target in Drug Development
Volume: 6 Issue: 8
Author(s): Cristina Missale, Chiara Fiorentini, Chiara Busi, Ginetta Collo and P. F. Spano
Affiliation:
Keywords: glutamate transmission, cAMP-PKA pathway, bioluminescence resonance energy transfer (BRET), NMDA-mediated currents, Dopamine
Abstract: Dopamine and glutamate have been shown to extensively interact in the striatum, nucleus accumbens, hippocampus and prefrontal cortex, to regulate different physiological functions, including locomotor activity, positive reinforcement, attention and working memory. Although dysfunctions of dopamine transmission have long been identified as critical determinants of neurological and neuropsychiatric disorders, such as Parkinsons disease and schizophrenia, there is now increasing evidence that concurrent alterations of dopamine and glutamate function may play a central role in the pathophysiology of these diseases. Thus, defining the characteristics of dopamine-glutamate interactions may be crucial to identify alternative molecular targets for the development of novel pharmacological tools. At the postsynaptic level, interactions between the dopamine D1 and the glutamate NMDA receptors appear to be particularly relevant. Different mechanisms are involved in this interactions: 1) D1R-dependent, second messenger-mediated phosphorylation of NMDAR subunits; 2) coordinated regulation of receptor trafficking at synaptic sites; 3) formation of an heteromeric D1/NMDA receptor complex. In this paper we review the molecular mechanisms, functional implications and pharmacological significance of D1R/NMDAR interaction via direct protein-protein oligomerization.
Export Options
About this article
Cite this article as:
Missale Cristina, Fiorentini Chiara, Busi Chiara, Collo Ginetta and Spano F. P., The NMDA/D1 Receptor Complex as a New Target in Drug Development, Current Topics in Medicinal Chemistry 2006; 6 (8) . https://dx.doi.org/10.2174/156802606777057562
DOI https://dx.doi.org/10.2174/156802606777057562 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Synthesis of L-Dopa Modifier L-Dopa-L-His and its Interaction with DNA
Letters in Organic Chemistry TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Editorial (Thematic Issue: Recent Progress in Drug Discovery for Parkinson's Disease)
Current Topics in Medicinal Chemistry An Outline of the Historical and Clinical Aspects of Catatonic Schizophrenia
Current Psychiatry Reviews Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimers Disease
Current Alzheimer Research Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Novel Insight into Cholinergic Factors Associated with Schizophrenia and Autoimmunity
Current Immunology Reviews (Discontinued)